MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers

Abstract

Microsatellite instability (MSI) is displayed by approximately 15% of colorectal cancers (CRC). Defective DNA mismatch repair generates mutations at repetitive DNA sequences such as those located in the double strand break (DSB) repair gene MRE11. We assessed the mutational status of MRE11 in a panel of 17 CRC cell lines and 46 primary tumors and found a strong correlation with MSI status in both cell lines and tumors. Therefore, we hypothesized that deficiency in MRE11 may sensitize CRC cells to poly(ADP-ribose) polymerase (PARP-1) inhibition based on the concept of synthetic lethality. We further assessed the activity of the PARP-1 inhibitor, ABT-888, in CRC cell lines and observed preferential cytotoxicity in those MSI cell lines harboring mutations in MRE11 compared with both wild-type cell lines and microsatellite stable (MSS) cell lines. A significant correlation between MRE11 expression levels and cytotoxicity to ABT-888 at 10 mM was observed (R 2 ¼ 0.915, P < 0.001). Using two experimental approaches, including short hairpin RNA knocking down MRE11 in the wild-type and MSS cell line SW-480 and a second cell line model transfected with mutant MRE11, we experimentally tried to confirm the role of MRE11 in conferring sensitivity to PARP-1 inhibition. Both models led to changes in proliferation in response to ABT-888 at different concentrations, and a drug-response effect was not observed, suggesting a possible contribution of additional genes. We conclude that MSI colorectal tumors deficient in DSB repair secondary to mutation in MRE11 show a higher sensitivity to PARP-1 inhibition. Further clinical investigation of PARP-1 inhibitors is warranted in MSI CRCs. Cancer Res; 71(7); 2632-42. Ó2011 AACR.

Impact of chemotactic factors and receptors on the cancer immune infiltrate: a bioinformatics study revealing homogeneity and heterogeneity among patient cohorts

“…Five different datasets were included for several major cancer types, in particular breast carcinoma (TCGA consortium), 31–34 colorectal carcinoma (http://www.intgen.org or TCGA consortium), 35,36 non-small cell lung carcinoma (TCGA consortium) 37–40 and melanoma, 41–45 to study the correlation between the expression level of metagenes indicating the presence of immune cell types and a variety of chemotactic factors and receptors. An extra dataset concerning breast carcinoma 46 was used for studying expression variability and treatment response.…”

Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

“…Support for this hypothesis can be found in a report by Vilar et al, in which they noted that a deficiency in MRE11 sensitizes colorectal cells to PARP-1 inhibition. This group tested 17 colorectal cell lines and 46 primary tumors and found that MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in MSI-H colorectal cancers exhibiting biallelic mutation in MRE11 [24]. Because biallelic mutations represent 36% of all MRE11 mutations, if we had honed our target of MSI-H patients to those with MRE11 biallelic mutations, it is possible we would have had a better outcome.…”

Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer

“…Abnormal MMR expression was identified in 6% of CCC (33). Defective DNA MMR generates MRE11 mutations and sensitizes cancer cells to PARP1 inhibition, showing the synthetic lethality between MRE11 and PARP1 (41). MSH6 is a synthetic lethality partner of: dihydrofolate reductase; DNA polymerase β, catalytic subunit; DNA polymerase γ, catalytic subunit; or PTEN-induced putative kinase 1. mTOR pathway genes are often mutated in CCC (42).…”